Real-world data and evidence in the development of cell and gene therapies

Journal of Biopharmaceutical Statistics · Published 2026-03-29 · DOI 10.1080/10543406.2026.2648311

Authors being retrieved — see the publisher record. https://doi.org/10.1080/10543406.2026.2648311

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Statistical approaches to classify investigational product using hERG safety assay · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Advances in statistical methodologies for assessing bioequivalence of topical dermatological products · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Robust CATE estimation using novel ensemble methods · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Augmented match weighted estimators: new methods for estimating average treatment effects under extreme propensity scores · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Non-inferiority testing for the odds ratio in two independent binomial proportions using the method of variance estimates recovery · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Bayesian quantitative decision-making framework in cell and gene therapy development for rare diseases · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Analyze paired case–control data prospectively in comparing two predictive values · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Parallelism of four-parameter logistic bioassay models: equivalence testing for parameter differences* · Journal of Biopharmaceutical Statistics · 2026 · Same journal
• Tolerance and prediction intervals: The Bayesian way · Journal of Biopharmaceutical Statistics · 2026 · Same journal